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ABSTRACT  OBJECTIVE: Our previous study employing a rat heterotopic abdominal heart 
transplantation model (Ono-Lindsey method) showed that significantly less myocardial scar 
tissue was formed in both the Tb4 plasmid and Tb4 peptide groups compared to controls. In 
the present study, myocardial infarction was induced in the normal working rat heart and the 
effect of the Tb4 plasmid on myocardial scar formation was examined.
MATERIALS & METHODS: The left anterior descending branches of the left coronary artery of 
rats were ligated to induce broad antero septal myocardial infarction. Rats were divided into the 
following 2 groups: Tb4 plasmid (50 μg/50 μl) group and empty vector injection control group. 
In each group, the drug was injected at 2 or 3 sites in the myocardial infarct area. Myocardial 
tissue, harvested 4 weeks later, was evaluated using Masson trichrome staining, and the 
myocardial scar volume was measured. In addition, expression of the plasmid at the local 
myocardium was detected in the plasmid group 1 week later by immunostaining.
RESULTS: The immunostain revealed Tb4 expression in the myocardial infarct area where the 
Tb4 plasmid had been injected. Myocardial scar volume was significantly lower in the Tb4 
plasmid group (19.5±4.6%, n ＝21, p ＝0.019 vs control) than in the control group (23.4±4.7%, 
n ＝15). 
CONCLUSION: Significantly less myocardial scar tissue was formed in the Tb4 plasmid group 
compared with the control group. The Tb4 plasmid can reduce myocardial scar volume in 
myocardial infarction by means of the expression of Tb4.
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INTORODUCTION
   Thymosin beta 4 (Tb4) was first isolated from 
calf thymus approximately 40  years ago. It 
belongs to a family of highly conserved polar 
5-kDa peptides consisting of 40‒44 amino acids. 
In most mammalian tissue, Tb4  is the main 
peptide, representing approximately 70‒80% of 
total beta-thymosin content1）. Tb4 is present in 
very high concentrations in white blood cells and 
thrombocytes among other tissues2）. In addition to 
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acting as a simple actin monomer buffering protein, 
recent studies have revealed that beta thymosins are 
multifunctional peptides involved in cell migration, 
angiogenesis, wound healing, inflammation, 
morphogenesis, and tumor metastasis2‒9）. While 
investigating the vasculogenic potential of Tb4, 
Grant and coworkers found that Tb4 mRNA increases 
5-fold during the morphological differentiation 
of endothelial cells into capillary-like tubes10）. 
Moreover, both Malinda et al11） and Grant et al12） 
reported that Tb4 stimulates cell-matrix attachment, 
proliferation, tube formation, peptide internalization, 
and rearrangement of the actin cytoskeleton. A recent 
topic of interest concerning Tb4 is its involvement 
in the prevention and repair of cardiac damage 
after myocardial infarction in mice by promoting 
cardiac cell migration and survival13）. Other studies 
have identified Tb4-induced adult epicardial cells 
as a viable source of vascular progenitors for the 
continued renewal of regressed vessels at a low 
basal level or for sustained neovascularization 
following cardiac injury14）. These findings suggest 
that Tb4 promotes cardiomyocyte migration, 
survival, and repair, and the pathway it regulates 
may be a new therapeutic target for the treatment of 
acute myocardial damage. Bock-Marquette et al13） 
reported that Tb4 formed a functional complex with 
particularly interesting new cysteine-histidine-rich 
(PINCH) proteins and integrin-linked kinase (ILK), 
resulting in activation of the survival kinase Akt (also 
known as protein kinase B). In mice subjected to 
coronary artery ligation, Tb4 treatment upregulated 
ILK and Akt activity in the heart, enhanced 
early myocyte survival, and improved cardiac 
function. Based on the results of these studies, the 
administration of Tb4 for the repair of an infarcted 
myocardium may be more effective and easier than 
the conventional strategy involving isolating and 
implanting hematopoietic stem cells. 
   In our previous study which used a rat heterotopic 
abdominal heart transplantation model9） (the Ono-
Lindsey method15）), significantly less myocardial 
scar tissue formed in both the Tb4 plasmid and Tb4 
peptide groups compared with a control group. In 
the present study, the effect of the Tb4 plasmid on 
the suppression of scar formation was evaluated, 
after myocardial infarction was induced in a normal 
working rat heart.
MATERIALS AND METHODS
   Experimental procedures and protocols were 
approved by the Animal Research Committee of 
Kawasaki Medical School, Kurashiki, Japan, and 
were performed in accordance with institutional 
guidelines.
Animal preparation
   Male Lewis rats (250‒300 g; n=36; Charles 
River Laboratories Japan, Yokohama, Japan) 
were premedicated with ketamine (90 mg/kg) 
and xylazine (10 mg/kg) and orally intubated. 
Respiration was controlled mechanically by 
Sevoflurane inhalation (1.0‒3.0%, with 100% 
oxygen; Anaesthesia WorkStation, Hallowell EMC, 
Pittsfield, MA). Body temperature was controlled 
with an electric heating pad and surgery was 
performed using aseptic techniques.
Injection of Tb4
   After entering the left thoracic cavity by 
thoracotomy, the left anterior descending branches 
of the left coronary artery were ligated with 7-0 
polypropylene suture (Prolene® ; Ethicon, Inc., 
Somerville, NJ) and the rats were divided into 
the following 2 groups: the Tb4 plasmid (50μg 
/50μl) group and the empty vector injection 
control group. In each group, drugs were injected 
at 2 or 3 sites of the myocardial infarction area. 
Myocardial tissue was harvested 4 weeks later, 
and the suppressive effect of Tb4 on the volume of 
myocardial scar formed was evaluated. In addition, 
cardiac tissue from the plasmid group was extracted 
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1 week after treatment and expression of the 
plasmid was confirmed by beta galactosidase and 
immunostaining. Tb4 was obtained from Y. Osawa 
(Fig. 1, 2).
Fig. 1.　Structure of the thymosin beta 4 (Tb4) plasmid DNA
Fig. 2.　Experimental method ﬂow chart
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Immunohistochemical and morphometric analysis
   Myocardial tissue was snap frozen in liquid 
nitrogen-cooled isopentane and sectioned transversely 
(10μm) at the center of the cardiac muscle using a 
cryostat (Model, Leica Microsystems, City, Country/
US state) with an A35 Microtome Blade (Tech-Jam, 
City, Country/US state) as reported previously17,18）. 
Sections were postfixed in 1% formalin in 
phosphate buffered saline (PBS) for 10 min and 
immunostained according to the MOM procedure 
(Vector Mouse on Mouse Kit, Vector Laboratories, 
City, Country/US state) using rabbit polyclonal 
antibody (Ab) against caveolin-3 (BD Biosciences, 
City, Country/US state) using rat FITC-conjugated 
secondary Ab. 
Measurement of volume of myocardial scar 
formation and statistics
   The extracted myocardial specimens were 
Fig. 3.　Beta galactosidase staining of rat cardiac muscle
In beta galactosidase staining of the myocardium, the plasmid was ingested into a cell and stained blue (arrows).
evaluated using Masson trichrome staining, and 
the myocardial scar volume was measured. IPLab 
for Windows (Solution Systems, City, Country/US 
state) software was used for image processing and 
analysis. Statistical calculations were performed 
using a standard t-test for variables with 95% 
confidence intervals.
RESULTS
   In beta galactosidase staining of the myocardium, 
the plasmid was ingested into a cell and stained 
blue (Fig. 3, arrows). Immunostaining revealed 
Tb4 expression in the myocardial infarct area, 
which was strongly stained (Fig. 4, arrows). Tb4 
was expressed in the parts of myocardium where 
Tb4 plasmid was injected, and the expression was 
observed in one or two cells per one field of vision 
under the microscope. The volume of myocardial 
scar tissue was 19.5±4.6% and 23.4±4.7% in the 
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Tb4 plasmid group (n＝21) and the control group (n
＝15) respectively. The volume of myocardial scar 
tissue formed was significantly lower in the Tb4 
plasmid group (19.5±4.6%, n＝21, p＝0.019 vs 
control) than in the control group (23.4±4.7%, n＝
15) (Fig. 5). 
Fig. 4.　Immunostaining of rat cardiac muscle
Immunostaining revealed Tb4 expression in the myocardial infarct area, which was strongly stained (arrows). The sites of Tb4 
expression corresponded to the parts of the myocardium where Tb4 plasmid had been injected.
Fig. 5.　Comparison of myocardial scar volume between the Tb4 plasmid group and control group
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DISCUSSION
   Bock-Marquette et al13） reported that the ability of 
Tb4 to prevent cell death within 24 h of coronary 
ligation is probably responsible for the decreased 
scar volume and improved ventricular function 
observed in mice. Although Tb4 activation of 
ILK is likely to have many cellular effects, the 
activation of Akt may be the dominant mechanism 
through which Tb4 promotes cell survival. Smart 
et al14） reported that coronary vasculogenesis is 
required to maintain cardiomyocyte survival and 
consequently appropriate myocardial architecture 
and cardiac function; the role of Tb4 in coronary 
vessel development may underlie its reported ability 
to play a therapeutic role in cardioprotection and 
repair. 
   In our previously study, the condition of rats 
stabilized after a heart transplant in which ligation 
of both the left anterior descending branches and 
circumflex branches of the left coronary artery 
of the donor heart was performed. This model 
demonstrated the effect of occlusion of the main 
trunk of the left coronary artery. Consequently, we 
considered that the grafted myocardial tissue might 
be in a ready state for regeneration because in this 
rat heterotopic abdominal heart transplantation 
model, the transplanted heart worked in the 
condition of non-working beat. In the present study, 
therefore, myocardial infarction was induced in a 
normal working heart and the effect of injecting Tb4 
plasmid on cardiac repair was examined. As a result, 
myocardial scar volume was significantly less in the 
Tb4 plasmid group than in the control group.
   Tb4 can be administered safely to both Sprague-
Dawley rats and cynomolgus monkeys at doses 
of up to 50 mg/kg and was well tolerated in both 
species at all doses tested16）. The dose of Tb4 for 
this study was fixed based on report13） in which 0.4 
μg of Tb4 was injected intramyocardially and 150 
μg of Tb4 was administered intraperitoneally to 
mice. In our previous study, acceptable scar volume 
results were obtained by the administration of 4.0 
μg of Tb4 peptide or 50μg of Tb4 plasmid16）. 
Therefore, a similar dose of Tb4 plasmid was used 
in the present study.
   Beta galactosidase and immunostaining revealed 
the positive effects of introducing Tb4 into the 
myocardium and visualized Tb4 in the myocardial 
infarct area. This is the first report documenting 
the appearance of Tb4 at the same sites where 
Tb4 plasmid had been injected. 
   The effect of the Tb4 plasmid on suppression of 
myocardial scar formation was also demonstrated in 
this study. However, as only a low quantity of Tb4 
was introduced into the myocardium, it is thought 
that increasing the quantity of Tb4 plasmid is 
important to induce a greater effect. The mechanism 
by which Tb4 induces myocardial reformation, 
vascularization, ischemic defense, and cell survival 
in myocardial repair remains to be clarified. Such 
important issues need to be addressed in future 
studies.
SUMMARY
   The effect of the Tb4 plasmid injected into the 
myocardial tissue on suppression of myocardial 
scar formation was examined by using a myocardial 
infarction model in a normal working rat heart. 
Immunostaining revealed Tb4 expression in the 
myocardial infarct area where the Tb4 plasmid was 
injected. As a result, myocardial scar volume was 
significantly less in the Tb4 plasmid group than in 
the control group. Therefore, the use of Tb4 is of 
therapeutic interest in the field of myocardial repair.
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